Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ResMed Inc. filings document operating results, governance actions, capital returns and securities registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and fiscal-year financial results, record board-declared cash dividends and describe the treatment of NYSE common stock and ASX CHESS Depositary Interests in dividend payments.
The company’s regulatory record also covers board composition, director elections, executive officer transitions, compensation arrangements and amendments to the ResMed Inc. 2009 Incentive Award Plan. Proxy materials provide stockholder voting matters, executive compensation disclosure and corporate-governance information for the medical technology company’s public-company structure.
ResMed (RMD) insider Michael Farrell has filed to sell common shares under Rule 144. The notice covers 4,991 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 1,366,436.43 and 145,678,401 common shares outstanding.
The 4,991 shares were acquired on 02/09/2026 via an option originally granted on 11/21/2019, with the purchase price paid in cash. The filing also lists sales over the prior three months: 4,991 common shares on 12/08/2025 for gross proceeds of 1,254,795.79 and 4,991 common shares on 01/07/2026 for 1,240,065.36.
By signing the notice, the seller represents that he does not know of any undisclosed material adverse information about ResMed’s current or prospective operations.
ResMed Inc. director Peter C. Farrell, who serves as chairman emeritus, reported selling 2,000 shares of ResMed common stock on February 4, 2026 at a price of $251.31 per share. After this transaction, he beneficially owned 64,773 shares directly. The sale was executed under a pre‑arranged Rule 10b5‑1 trading plan that was adopted on August 12, 2025, indicating the trade followed an advance, systematic plan rather than a discretionary same‑day decision.
ResMed Inc.'s Global General Counsel Michael J. Rider reported a small automatic share sale under a pre-set trading plan. On 02/04/2026, he sold 50 shares of ResMed common stock at $260 per share in a transaction coded as a sale.
After this trade, he beneficially owned 9,691 shares, all reported as directly held. The filing notes that the transaction was conducted under a Rule 10b5-1 plan adopted on February 28, 2025, indicating it was pre-arranged rather than a discretionary market-timed trade.
A shareholder, Peter C Farrell, has filed a notice of intent to sell 2,000 shares of common stock through Merrill Lynch on the NYSE. The planned sale has an aggregate market value of 502540, with 44,448,959 shares of the issuer’s stock reported as outstanding and an approximate sale date of 02/04/2026.
The 2,000 shares were acquired on 11/11/2014 via a stock option transaction for cash. Over the prior three months, Peter C Farrell sold 2,000 shares on each of three dates, with gross proceeds of 504020, 502860, and 497580, indicating a pattern of periodic share sales.
A shareholder in RMD filed a Form 144 notice to sell 50 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 13000.00, on or about 02/04/2026 on the NYSE. The 50 shares were acquired as restricted stock vesting on 11/11/2021 as compensation from the issuer. Over the past three months, the same account has sold 50 shares of common stock on 12/01/2025 for gross proceeds of 12208.00 and another 50 shares on 01/02/2026 for gross proceeds of 12087.50.
ResMed Inc.’s Chief Financial Officer Brett Sandercock reported a planned sale of company stock. On February 2, 2026, he sold 1,000 shares of ResMed common stock at $257.03 per share under a Rule 10b5-1 trading plan adopted on February 19, 2025.
After this transaction, Sandercock directly holds 85,495 ResMed shares. Rule 10b5-1 plans allow executives to pre-schedule trades, helping separate routine portfolio moves from day-to-day market or company news.
Brett Sandercock filed a notice of proposed sale of 1,000 shares of common stock with an aggregate market value of 257,030.00, to be sold through Fidelity Brokerage Services LLC on the NYSE around 02/02/2026.
The 1,000 shares were acquired on 11/11/2022 through restricted stock vesting from the issuer as compensation. Over the prior three months, Brett Sandercock sold 3,000 common shares on 11/03/2025 for gross proceeds of 742,620.00, 1,000 shares on 12/01/2025 for 244,160.00, and 1,000 shares on 01/02/2026 for 241,750.00.
ResMed Inc. reported solid quarterly growth, with net revenue for the three months ended December 31, 2025 rising to $1.42 billion, up 11% from a year earlier (9% in constant currency). Sleep and Breathing Health products drove most of the increase, with devices and masks both seeing higher demand and unit sales across the U.S., Canada, Latin America, Europe, Asia and other markets.
Residential Care Software revenue grew 7% to $166.9 million, helped by strength in the MEDIFOX DAN and Home and Hospice verticals, partly offset by softer Senior Living and Long-Term Care performance. Company-wide gross margin improved to 61.8% from 58.6%, mainly due to manufacturing and logistics efficiencies and lower component costs.
Net income for the quarter grew to $392.6 million, with diluted earnings per share increasing to $2.68 from $2.34. For the first six months of the fiscal year, revenue reached $2.76 billion, up 10%, and gross margin rose to 61.6%. ResMed ended the period with $1.42 billion in cash and cash equivalents and $6.32 billion in stockholders’ equity, providing a sizable financial cushion alongside its global growth initiatives.
ResMed Inc. filed a current report describing its latest quarterly results and a new dividend declaration. The company issued a press release covering operations for the quarter ended December 31, 2025, which is furnished as an exhibit and not treated as filed for liability purposes.
ResMed’s board declared a quarterly cash dividend of US $0.60 per share, with a record date of February 12, 2026, payable on March 19, 2026. The dividend will be paid in U.S. dollars to NYSE common stockholders. Holders of CHESS Depositary Instruments on the ASX will receive the equivalent in Australian dollars based on the exchange rate on the record date, reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date is February 11, 2026 for both common stock and CDIs, and ResMed obtained an ASX waiver to defer conversions between its common stock and CDI registers from February 11–12, 2026.
ResMed Inc. director Peter C. Farrell reported a sale of company stock. On January 7, 2026, he sold 2,000 shares of ResMed common stock at a price of $248.83 per share. After this transaction, he beneficially owned 66,773 shares directly. The filing notes that the trade was conducted under a Rule 10b5-1 trading plan that was adopted on August 12, 2025, which is a pre-arranged plan that allows insiders to systematically sell shares over time.